IDEXX (IDXX) Surges 22% on Q3 Beat and Higher 2026 Outlook

IDEXX Laboratories (IDXX) stock jumped about 22% after third-quarter earnings of $4.01 a share topped estimates and the company raised its 2026 outlook.

Lead

What Did IDEXX Report for the Third Quarter?

IDEXX reported organic revenue growth of 10% and an operating margin of 33.1%, up 100 basis points from a year earlier and 60 basis points on a comparable basis. Growth came mainly from the company's recurring diagnostics business, where revenue from lab services, consumables and rapid tests rose 11% both as reported and organically.

Geography was uneven. U.S. organic recurring diagnostics revenue grew 9.6%, while international recurring revenue grew 14% organically, with double-digit gains across major regions.

The company placed 5,780 premium instruments in the quarter, including 1,904 inVue Dx analyzers. Each placed instrument adds to the installed base that generates repeat consumables and testing revenue, which is the core of the IDEXX business model.

Why Did IDEXX Shares Rise So Sharply?

IDEXX shares rose because results showed diagnostics demand growing well ahead of veterinary clinic traffic, easing a concern that had weighed on the stock. Same-store clinical visits fell 1.8% in the quarter. Diagnostics revenue still outpaced visit trends by more than 1,100 basis points. Higher testing frequency per visit, an aging pet population and wider adoption of newer instruments drove that gap.

The guidance increase reinforced the signal. A 20% single-session gain is unusual for a large-cap healthcare company, and it reflects how much the earnings and forecast changed the growth outlook.

How Much Did IDEXX Raise Its 2026 Outlook?

IDEXX raised its 2026 revenue forecast to $4.741 billion-$4.767 billion and its EPS forecast to $14.96-$15.16, up from $14.69-$14.94. Organic revenue growth guidance moved to 9.3%-10.0% from 8.5%-9.7%.

For the recurring diagnostics business, the company now expects reported growth of 11.0%-11.7% and organic growth of 10.3%-11.0%. Full-year operating margin is projected at 32.1%-32.3%.

Strategic Context

The quarter showed IDEXX's strategy of pairing premium instrument placements with software and AI-enabled workflow tools. The company also pointed to its integration of CoVet, a clinical software platform, as part of an effort to deepen its presence in veterinary practices.

The pattern matters because clinic visits are the weak spot in the pet-health sector. If diagnostics can keep growing while visits fall, IDEXX's revenue depends more on testing intensity per patient and less on traffic. The third-quarter figures support that view.

What Comes Next for IDEXX?

The next test is whether diagnostics growth can keep outpacing clinic visits as comparisons toughen. U.S. visit declines and international momentum will both shape the fourth-quarter results. The raised guidance range implies continued double-digit growth in recurring diagnostics through year-end.

The size of the rally also resets the stock's valuation. IDXX now trades far above its pre-earnings level, so future quarters will be judged against a higher bar for premium placements, margin expansion and recurring revenue.

Outlook

IDEXX delivered a 10% revenue increase, a 33.1% operating margin and a higher 2026 forecast, and the market responded with a roughly 22% one-day gain. Diagnostics demand now outweighs the drag from lower clinic visits. The path ahead depends on continued instrument placements and testing frequency.